All In Biotech

Drug Trial Radar · NCT03326063

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease

Last checked: Nov 19, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Apr 26, 2018

Primary completion

Mar 30, 2022

Study completion Apr 15, 2023

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 30, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).

Conditions

  • Nasal Polyps
  • Asthma, Aspirin-Induced
  • Aspirin-exacerbated Respiratory Disease
  • Aspirin-Sensitive Asthma With Nasal Polyps

Interventions

  • IfetrobanDrug

    4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD

  • PlaceboDrug

    4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Provocative Dose 2 (PD2) During Aspirin ChallengeTime frame: 6 weeks from screening visit ( at visit 2)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asthma Research Center, Brigham and Women's Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.